Dual Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

Last updated: March 13, 2025
Sponsor: University of Edinburgh
Overall Status: Active - Recruiting

Phase

2

Condition

Polymyalgia Rheumatica (Pmr)

Connective Tissue Diseases

Dermatomyositis (Connective Tissue Disease)

Treatment

Bosentan

Clinical Study ID

NCT06887062
AC24184
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Large vessel vasculitis is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes. A chemical produced in the body called endothelin may contribute to this increase in cardiovascular disease risk by causing the vessels to stiffen and blood pressure to increase.

It has previously been shown that by blocking the effects of endothelin, vessel stiffness and blood pressure improve. Bosentan is a tablet that blocks the effects of endothelin. The investigators plan to assess blood vessel function in those with LVV and participants without LVV. Participants with LVV will then be given Bosentan for 6 weeks to evaluate its impact on blood vessel function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • A diagnosis of large vessel vasculitis that has been in remission for ≥ 6 months.

Exclusion

Exclusion Criteria:

  • Age <18 years

  • Active LVV

  • Any organ transplant recipients

  • A requirement for any medications that are contra-indicated whilst taking Bosentan

  • Congestive cardiac failure

  • Patients not medically fit to attend study visits

  • Patients without mental capacity or willingness to provide informed consent

  • History of multiple and/or severe (clinical judgement as determined by theInvestigator) allergic reactions to drugs, including the study drug, or food

  • Patients who are pregnant or breast feeding, or those who plan to become pregnantduring the study

  • Participation in another clinical trial for 28 days before or 90 days after thestudy period

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Bosentan
Phase: 2
Study Start date:
March 21, 2025
Estimated Completion Date:
July 01, 2027

Study Description

Large vessel vasculitis (LVV) is an autoimmune disease characterised by inflammatory damage to the blood vessels. Although symptoms initially are non-specific, complications such as vessel stenosis can lead to heart failure and stroke. While current immunosuppressive treatments have improved short-term outcomes, they have not led to improvements in long-term outcomes. Patients with LVV remain at an increased risk of developing cardiovascular disease, the underlying mechanisms of which are not yet fully understood.

The inflammatory damage to blood vessels in LVV can result in endothelial dysfunction. Endothelin-1 (ET-1) is a potent vasoconstrictor produced by the endothelium. In endothelial dysfunction, excess ET-1 production causes raised blood pressure, increased arterial stiffness and reduced fibrinolytic capacity. Previous research has demonstrated that short-term blockade of endothelin receptors improves arterial stiffness and fibrinolytic capacity.

The investigators will conduct a cross-sectional, case-control study comparing endothelial function in patients with LVV with sex-, age-, and cardiovascular disease risk factor-matched control participants. This will be followed by an open-label study involving 6 weeks of treatment with Bosentan (a dual endothelin receptor antagonist) within the LVV group to assess whether this drug can improve endothelial function. Assessment of endothelial function will be carried out by forearm plethysmography which is the gold standard.

Connect with a study center

  • University of Edinburgh

    Edinburgh, EH16 4TJ
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.